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Abstract
The formation of a nodule within a congenital melanocytic nevus (CMN) raises concerns about 
possible melanoma. Most new nodular growths that develop during childhood, however, are 
benign proliferative nodules (PN); melanoma is very rare. The distinction of melanoma from PN 
can at times be difficult clinically and histopathologically, requiring ancillary molecular tests for 
diagnosis. While the application of molecular methods has revealed new insights into the 
mutational and genomic landscape of childhood melanomas, little is known about epigenetic 
events that may drive the growth of a melanoma or PN in a CMN. In this study we compared the 
expression of H3K27me3, a key regulator in chromatin remodelling-controlled transcription, in 
PNs and pediatric nodular melanomas arising within medium-sized to large CMN by 
immunohistochemistry (IHC). Significant loss of H3K27me3 expression was seen in four of five 
melanomas, but not in any of the 20 PNs. This observation suggests that epigenetic events likely 
play a role in the pathogenesis of melanoma developing in the dermis or subcutis of CMN. 
Furthermore, assessing for H3K27me3 expression by IHC may be diagnostically useful for 
problematic cases.
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New nodules may form within a congenital melanocytic nevus (CMN). The majority of 
these are benign proliferative nodules (PNs), but on rare occasion a melanoma may develop 
within the dermal or subcutaneous compartment of a large melanocytic nevus 1–4. The 
incidence with which PNs develop has been estimated to range from 3 - 20% in giant 
CMN1, 5, 6. The incidence of cutaneous melanoma arising in CMN of all sizes and numbers 
considered together is lower, of the order of less than 1% to 3%7–10. However this varies 
substantially with the severity of the clinical phenotype.
In most children a PN can reliably be distinguished from melanoma by clinico-pathologic 
correlation. Clinically, a PN typically differs from melanoma by uniformity of color and 
outline, a tendency to stabilize, and lower likelihood to ulcerate. Histopathologically, the 
melanocytes of a PN tend to blend in with those of the background nevus, but nonetheless 
form a microscopically distinct nodule due to their hypercellularity. There is a range of 
histopathologic appearances of PNs from small to large epithelioid to fusiform, blue or Spitz 
nevus-like, pigmented or amelanotic6, 11. Sometimes a nodule may display mesenchymal 
features under the microscope12. In general, melanomas are more abruptly demarcated from 
the surrounding nevus, display a higher degree of nuclear atypia, and many more tumor cells 
are seen in mitosis11. In melanoma, there may be apoptotic bodies or even frank tumor 
necrosis.
Some melanomas display marked nuclear pleomorphism, numerous mitoses and tumor 
necrosis, making their recognition as a malignancy by light microscopic examination 
straightforward. However, especially on a partial biopsy, the distinction of a PN from 
melanoma can be difficult, in particular when the level of atypia and number of mitoses are 
in a grey zone, i.e., at a level that can be seen both in association with a benign as well as a 
malignant tumor, or the nodule has spitzoid or undifferentiated mesenchymal features. In 
those cases, ancillary genetic studies may assist in the diagnostic work-up. In the past 
decade, cytogenetic analysis has emerged as a useful adjunct method for the distinction of 
melanoma from PN11, 13. Melanomas tend to show segmental chromosomal gains and/or 
losses involving different chromosomes while PNs either may not contain any detectable 
cytogenetic aberrations or may carry whole chromosome gains or losses11, 13–15, but there 
are rare exceptions16. Furthermore interpretation of these techniques typically requires some 
experience or expertise in assessing cytogenetics in melanocytic neoplasia.
Much has been learned in recent years about the mutational landscape of melanomas17. 
Melanomas in adults, the vast majority of which arise at the dermal-epidermal junction, tend 
to be rich in mutations, with variations in mutation type and number depending on anatomic 
site and extent of sun-exposure18, 19. Preliminary evidence of mutational analyses of 
childhood melanomas indicates that conventional (“adult-type”) melanomas affecting the 
skin surface of children also carry UV-mutations and commonly harbor BRAFV600 
mutations20. However, pediatric melanomas associated with CMN tend to lack UV-
mutations and have a lower mutational burden 20(KJB, unpublished data). Given the distinct 
clinical setting and behavior (lack of UV exposure, onset of rapid tumor growth) we 
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speculated that epigenetic events may play a role in the development of subepidermal 
childhood melanomas arising in CMN.
The purpose of this study was to explore the possible role of epigenetic changes in 
subsurface nodular melanomas arising in CMN. As a marker for epigenetic changes we 
chose immunohistochemical expression of H3K27me3 21, 22. This marker was chosen 
because the assay conditions are well established in our laboratory, and it has been tested on 
melanomas before.
Materials and Methods
The work in this study was approved by the institutional review boards of both institutions. 
Twenty benign PMs and five nodular melanomas that arose in the dermal component of a 
CMN during childhood were selected and analyzed immunohistochemically. We also 
evaluated 10 primary melanomas from adults. Five micron thick sections were taken from 
formalin-fixed and paraffin-embedded tissue.
An automated immunohistochemistry system (Leica Bond, polymer) was used, with a 
commercially available antibody to H3K27me3 (Cell Signaling, clone C36B11).
Labeling was scored according to the percentage of immunoreactive tumor cells per total 
number of tumor cells: 0 = no staining; 1+ = 1-25% of tumor cells are positive; 2+ = 26-50% 
of tumor cells are positive; 3+ = 51-75% of tumor cells positive and 4+ = 76-100% of tumor 
cells are positive.
Genomic Analysis
Sequence analysis was performed on all five melanomas for clinical purposes. Two tumors 
were analyzed by FoundationOneR; two tumors were analyzed at Imperial College in 
London, UK; one tumor was analyzed at the Northwestern University Feinberg School of 
Medicine in Chicago, IL, with the PGM ion torrent 50 gene cancer panel (ThermoFisher, 
Waltham, MA).
The five melanomas were also analyzed cytogenetically. Melanoma case 1 was analyzed by 
FoundationOneR. Case 1 and 2 were analyzed by SNP array (OncoScanR). In case 3 array 
comparative genomic hybridization (CGH) was performed as per the manufacturer’s 
instructions, using Roche Nimblegen 135K oligonucleotide arrays and a sex-matched 
commercial pooled control. Cases 4 and 5 were analyzed by fluorescent in situ hybridization 
analysis (FISH), using probes for 6p, 6q, 6cent, 11q, and 8q23, 24.
Results
Clinical Findings
Of the 20 children with PNs, 11 were female and 9 were male. The mean age was 4.2 years; 
the median age was 2 years. Of the five children with a nodular melanoma arising in a CMN, 
three were girls and two of them were boys. Three of the children with melanoma also had 
preceding or concurrent proliferative nodules at other sites. Two children died of metastatic 
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melanoma. One of them was a boy (case 2) who died in his second year of life. He had a 
primary nodular melanoma that arose in perianal soft tissue in association with a giant 
bathing trunk CMN (measuring > 40 cm in largest dimension, 160 additional nevi). The 
other child with a lethal melanoma was a girl (case 3). She developed a nodular melanoma in 
a large CMN on the scalp (20cm projected adult size; multiple other melanocytic nevi from 
birth) at the age of 6 years. She died at age 7. The three other children are still alive, but with 
limited follow-up. One of them is a girl who developed a nodular melanoma on the scalp at 
the age of 8 years (case 1). Her melanoma arose in a CMN measuring 9 x 8 cm, with a 
predicted adult size of approximately 10 cm. The girl is still alive without evidence of 
disease 1 year after surgical removal of the primary tumor. The fourth child with a nodular 
melanoma is an infant girl. Her recently diagnosed melanoma was congenital and associated 
with a CMN of the scalp measuring 12 cm in greatest dimension. The sentinel lymph node 
and two of 28 non-sentinel regional lymph nodes were positive for tumor deposits. The girl 
is alive with follow-up of 5 months (October 2016). One patient is a teenage boy who 
developed a subsurface nodular melanoma at age 15 on the scalp at the site of a previously 
partially-excised CMN measuring 10 x 20 cm. He also had multiple other nevi. One of his 
regional lymph nodes was found to be positive for metastatic melanoma. He is currently 
alive and well with a follow-up of approximately 1 year.
Pathologic Findings
The histopathologic findings of the PNs are summarized in Table1 and representative 
examples are illustrated in Figures 1 - 3. Each PN was histopathologically characterized by a 
hypercellular expansile melanocyte proliferation in the dermis. Ten lesions were amelanotic. 
Focal melanin pigment was present in six nodules; four nodules were heavily pigmented 
throughout. Two of them resembled an epithelioid blue nevus. The dominant cell type in 12 
cases was round to oval (epithelioid) in morphology (Fig. 2). In five cases there was a mix of 
both spindle and epithelioid-shaped melanocytes. Three tumors were predominantly 
fusiform. Two tumors were associated with stromal sclerosis.
All melanomas presented as nodular dermal and/or subcutaneous tumors without associated 
in situ melanoma. The tumor cells displayed epithelioid cell features (Table 2, Figs. 4 – 7). 
In two cases they had a small round blue cell (melanoblastic) appearance with minimal 
visible cytoplasm (Fig. 4). In two cases the tumor cells were small to intermediate in size 
with enlarged nuclei and small amounts of pink cytoplasm. One of them contained a 
subpopulation of tumor cells with melanin pigment (Fig. 5); the other was predominantly 
amelanotic (Fig. 6). One case was composed of amelanotic large pleomorphic epithelioid 
tumor cells (Fig. 7) with pink cytoplasm. Mitoses were frequent (mitotic rate > 4/mm2) in all 
but one case. The mitotic rate of the large epithelioid cell nodule of the 15 year old boy (case 
5) had a mitotic rate of only 1/mm2.
Immunohistochemical Findings
All 20 PNs homogenously expressed H3K27me3. Nuclear expression was seen throughout 
the nodule as well as in the adjacent cells of the melanocytic nevus outside of the PN (Figs. 
1 - 3). Positive labeling was seen in > 80% of lesional cells of all 20 PNs.
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Marked reduction in labeling for H3K27me3 was seen in four prepubertal pediatric nodular 
melanomas that arose in a CMN (Table 2, Figs. 4 - 6), while the expression of H3K27me3 
was retained in the adjacent nevus and normal tissue. Among these four tumors, the extent of 
loss of labeling for H3K27me3 within the melanoma ranged from nearly complete (Figs. 4 
and 6) to approximately half of the tumor cells (Fig. 5). One nodular melanoma (case 5, 
Table 2), which developed on the scalp of a teenager, showed only minimal (approx. 10%) 
loss H3K27me3 expression (Fig. 7).
All ten adult melanomas retained expression of H3K27me3, but partial loss of labeling (< 
50% of tumor cells were immuno-negative) was seen in one acral melanoma (not shown).
Molecular Aberrations of Melanomas
The molecular aberrations detected in the nodular melanomas are summarized in Table 2. 
Three of the five tumors harbored NRAS mutations: two had an NRASQ61R, one an 
NRASG13R mutation. In two cases (cases 3 and 5) Sanger sequencing analysis of NRAS 
and BRAF confirmed NRASQ61R and BRAF wild-type mutation status in one case (case 
3). The other tumor (case 5) was confirmed to have wild-type mutation status for both 
NRAS and BRAF. In three cases, targeted next generation sequencing analysis was 
performed, which failed to reveal any mutation in case 2, detected a single NRASQ61R 
mutation in case 1, and documented a single NRASG13R mutation in case 4. All five 
melanoma cases had segmental chromosomal copy number aberrations. Genomic analysis 
documented numerous small segmental gains and losses involving different chromosomes in 
three of the four melanomas (cases 1, 3, 4 and 5). One lethal melanoma (case 2) contained 
only a single segmental gain of 6p by SNP array analysis. This melanoma was found to have 
a RAD18-BRAF fusion and small deletions involving PIK3CA, PIK3R1 and CTNNB1 by 
next generation sequence analysis (FoundationOneR).
Discussion
Much has been learned about the mutational landscape of melanomas17. The majority of 
melanomas in adults carry a high mutational burden, especially those tumors associated with 
chronic UV-damage18, 19. A recent study on a limited number of “childhood and 
adolescent” melanomas also identified a high number of mutations in conventional 
melanomas of teenagers and young adults (age range 11 to 20 years; median age = 16 years), 
with frequent BRAFV600 and TERT promoter mutations20. In contrast, each of the three 
melanomas associated with a CMN, which occurred in children younger than 5 years of age, 
contained an activating NRASQ61R mutation and no TERT promoter mutation20. It is of 
interest that the mutational burden of two of the three CMN melanomas was very low20. 
However, it is difficult to draw conclusions from this study about melanomas associated with 
CMN due to the small number of cases (only three) and lack of detail about the pathology of 
the melanomas20. It is not clear whether the melanomas associated with CMN developed at 
the dermal-epidermal junction or in the dermis/subcutis. The authors also failed to specify 
the phenotype of patients with the congenital nevi.
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We know, however, from prior studies that NRAS mutations are associated with melanomas 
of large CMN 2, 25, 26. Three of the five melanomas tested in this series also had an NRAS 
mutation.
The apparent paucity of the total number of mutations and the commonly observed rapid 
clinical growth of melanoma in early childhood made us suspect that epigenetic drivers may 
play a role in their pathogenesis. We also reasoned that epigenetic changes relevant in the 
pathogenesis of melanomas are likely different from benign PNs and could potentially be 
used for diagnostic purposes.
Among epigenetic events, post-translational modifications of the N-terminal cores of 
histones, such as by methylation, influences chromatin configuration and thereby modulates 
accessibility of transcription factors and transcriptional activity21, 27, 28. H3K27 
trimethylation (H3K27me3) is a well-known epigenetic gene silencer that can repress 
transcription. Polycomb repressive complexes 2 (PRC2) containing enhancer of zeste (EZH) 
2, a methyltransferase and core component of PRC2, are responsible for trimethylation of 
H3K2721. Aberrant expression of H3K27me3 has been found in different types of cancers 
and has been correlated with prognosis 22, 29. H3K27me3 expression levels can be assessed 
in formalin-fixed and paraffin-embedded tissues by immunohistochemistry and its 
expression pattern has recently been found to be useful for the distinction of malignant 
peripheral nerve sheath tumors from histologic mimics, including melanomas30, 31. We 
explored the role of epigenetic events in childhood melanomas arising in CMN by 
comparing H3K27me3 expression in benign PNs and nodular melanomas of medium-sized 
and large CMN.
Despite the rarity of bona-fide nodular melanomas arising in CMN of young children, we 
were able to analyze five tumors. Four of five tumors showed marked reduction in labeling 
of H3K27me3, from approximately half of the tumor cells in one case to more than 80% in 
the other three. One tumor showed minimal (approximately 10%) loss of labeling. It differed 
from the other tumors histopathologically by a large epithelioid cell phenotype, low mitotic 
rate and clinically by its occurrence in a teenager. In contrast to the majority of melanomas, 
all PNs retained expression of H3K27me3 expression in more than 80% of tumor cells.
The loss of H3K27me3 staining in melanomas of young children is of interest, since prior 
studies on H3K27me3 expression in melanomas suggested that this marker is typically 
retained 30, 31. Those melanomas, however, were from adults, with no documentation of an 
associated melanocytic nevus. Future studies of a larger set of different types melanomas 
from different age groups are needed to determine the expression pattern of H3K27me3 and 
its significance in various types of melanomas and at different clinical stages.
In conclusion, we report herein reduction of H3K27me3 expression in four of five nodular 
melanomas arising in the subepithelial compartment of a CMN during childhood. In 
contrast, H3K27me3 expression was retained or only mildly reduced in 20 benign PNs and 
the nevus cells adjacent to the melanoma nodules. These observations document for the first 
time that H3K27me3 expression can be markedly reduced in primary cutaneous melanoma. 
They indicate a likely role for epigenetic events in the pathobiology of at least some 
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pediatric nodular melanomas developing in CMN. Our results also suggest that H3K27me3 
expression has the potential to become an ancillary diagnostic tool for the distinction of a 
melanoma from an unusual PN. Since no major reduction in labeling for H3K27me3 was 
seen in any of the 20 benign PNs examined herein, loss of labeling for this marker should 
make one hesitate establishing a diagnosis of PN. One the other hand, retention of 
H3K27me3 expression can be seen in both PN and melanoma. Examination of a larger set of 
cases is necessary to assess the biologic significance of H3K27me3 expression in 
melanomas and its potential diagnostic value.
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Figure 1. Benign Proliferative Nodule
A: 4 year-old girl with nodular growth (circled) in a giant congenital nevus. B: A punch 
biopsy shows a densely cellular amelanotic nodule of melanocytes in the dermis. C: 
Transition area of nodule and background nevus: The nuclei are uniformly bland, but there is 
higher cellular density within the nodule. D: Both nevus and cellular nodule homogeneously 
label for H3K27me3.
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Figure 2. Proliferative Nodule.
A: Polypoid cellular nodule within a CMN. B: The lesional melanocytes express 
H3K27me3. C: The nodule is composed of a dense population of small to intermediate-sized 
cytologically bland amelanotic epithelioid melanocytes. D: The melanocytes within and 
adjacent to the nodule homogeneously show uniform nuclear labeling for H3K27me3.
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Figure 3. Congenital Proliferative Nodule of the Scalp
A: Polypoid nodule of epithelioid melanocytes. B: The nodular proliferation expresses 
H3K27me3. C: The nodular is composed of intermediate-sized epithelioid melanocytes. D: 
Most cells expresses H3K27me3.
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Figure 4. Lethal melanoma from a 15 month-old boy.
A: Congenital melanocytic nevus with a subcutaneous melanoma nodule. B: The compound 
melanocytic nevus involving epidermis and dermis is composed of cytologically bland cells 
with evidence of maturation. C: The nevus component retains expression of H3K27me3. D: 
The melanoma nodule is composed of discohesive round cells with little cytoplasm, mitoses 
and no maturation. D: Most melanoma cells lack expression of H3K27me3.
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Figure 5. Lethal melanoma from a 6 year-old girl.
A: The tumor is composed of epithelioid melanocytes with atypical nuclei. Some of them 
are pigmented. B. Approximately half of the tumor cells lack expression of H3K27me3.
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Figure 6. Congenital Melanoma of the Scalp (same patient as Figure 3)
A: Polypoid nodule of atypical epithelioid melanocytes with adjacent CMN. B: Little 
labeling for H3K27me3 is seen within the melanoma nodule while the adjacent melanocytic 
nevus is uniformly positive. C: The melanoma cells display an epithelioid cell appearance. 
The nuclei are enlarged and have irregular contours. Mitotic figures are present. D: The 
melanoma cells lack expression of H3K27me3.
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Figure 7. Nodular melanoma of the scalp at the site of a congenital nevus (15 year old boy).
A: Tumor nodule in soft tissue at the site of a previously incompletely excised congenital 
nevus. B: The tumor is sharply demarcated from the adjacent benign tissue. C: The tumor 
cells are large with pleomorphic nuclei and amelanotic pink cytoplasm. D: The majority of 
tumor cells express H3K27me3.
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Table 1
Clinical and pathologic features of benign proliferative nodules
Case Age Sex Site Cytology Melanin H3K27me3 - IHC
1 2 weeks F Scalp Epithelioid Absent 4+
2 4 years M Scalp Epithelioid Present 4+
3 11 weeks M Back Fusiform Absent 4+
4 10 months F Back Mixed Absent 4+
5 16 months F Scalp Epithelioid Present 4+
6 4 weeks M Back Fusiform Absent 4+
7 13 years M Back Epithelioid Present 4+
8 2 years F Abdomen Epithelioid Focal 4+
9 18 years M Scalp Epithelioid Focal 4+
10 5 years M Back Epithelioid Focal 4+
11 2 years F Scalp Mixed, sclerosing Focal 4+
12 3 years F Leg Mixed, sclerosing Absent 4+
13 9 years M Leg Epithelioid Absent 4+
14 Infant F Scalp Epithelioid Present 4+
15 14 years F Leg Epithelioid Focal 4+
16 5 years F Leg Epithelioid Focal 4+
17 5 years F Scalp Epithelioid Absent 4+
18 4 weeks M Back Fusiform Absent 4+
19 6 months F Back Mixed Absent 4+
20 4 years M Back Mixed Absent 4+
M = male; F = female
3 + = 51 – 75% of tumor cells are immunoreactive
4+ = more than 75% of tumor cells are immunoreactive
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Table 2
Clinical, pathologic and molecular findings of the nodular melanomas associated with a congenital 
melanocytic nevus
Case # Age (yrs) Sex Site Tumor Diameter Cytology Cytogenetics Mutations H3K27 IHC FU
1 8 F Scalp 9.4 mm Amelanotic small round 
blue
Multiple gains, losses NRAS c.182A>G, Q61R 1+ Alive (1 yr)
2 1 M Perianal soft tissue 14 mm Amelanotic small round 
blue
Gain of 6p RAD18-
BRAF fusion
None detected 1+ DOD
3 6 F Scalp 10 mm Pigmented small epithelioid Multiple gains, losses NRAS c.181C>A, p.Q61K 2+ DOD
4 Newborn F Back 7 mm Amelanotic small epithelioid Multiple gains, losses NRAS c.37G>C, G13R 1+ Alive (4mo)
5 15 M Scalp 8 mm Amelanotic large epithelioid Multiple gains, losses NRAS and BRAF wild 
type
4+ Alive (12 mo)
Abbreviations:
Yrs = years; F = female; M = male; IHC = immunohistochemistry; FU = follow-up DOD – dead of disease; mo = months
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